Hypertension and sensorineural hearing loss: relevance of the problem and the specifics of treatment (focus on Olmesartan)
https://doi.org/10.21518/2079-701X-2015-2-46-51
Abstract
Information about retraction of an article
Analysis conducted by the members of the editorial board has revealed the presence of direct borrowing without reference to the source of citations in the following articles:
The article by Evdokimova A.G., Yunko S.A., Gunchikov M.V. Arterial hypertension and sensorineural hearing loss: immediacy of the problem and treatment characteristics (focus on olmesartan) and the article by Baryshnikova G.A., Chorbinskaya S.A., Stepanova I.I The role of sartans in the treatment of hypertension: focus on olmesartan // Consilium Medicum – 2012 - No. 10 – p. 10-15.
Based on the decision of the Editorial Board of the journal Medical Council dated January 17, 2020, the following article has been retracted:
Evdokimova A.G., Yunko S.A., Gunchikov M.V. Hypertension and sensorineural hearing loss: relevance of the problem and the specifics of treatment (focus on Olmesartan)// Meditsinskiy sovet = Medical Council – 2015 - No.2 – p. 46-51.
Arterial hypertension (AH) is the most relevant risk factor for cardiovascular complications requiring adequate organ-protective treatment. In 17--19% of cases hypertension is combined with sensorineural hearing loss (SNHL). The article tells about antihypertensive therapy in patients with SNHL and mechanisms of its pathogenesis. A clinical case of long-term successful administration of olmesartan in a patient with AH and SNHL is described.
About the Authors
A. G. Evdokimova
Moscow State University of Medicine and Dnetistry named after A.I. Evdokimov; City Clinical Hospital №52
Russian Federation
Russian Federation
S. A. Yunko
Moscow State University of Medicine and Dnetistry named after A.I. Evdokimov; City Clinical Hospital №52
Russian Federation
Russian Federation
M. V. Gunchikov
National Medical and Surgical Centre named after N.I. Pirogov, Moscow
Russian Federation
Russian Federation
References
1. Рекомендации РМОАГ/ВНОК по диагностике и лечения артериальной гипертонии (IV пересмотр). 2010.
2. Куклина Е.В. Динамика кохлеовестибулярных нарушений у больных с начальными проявлениями недостаточности кровоснабжения мозга. Вестник отоларингологии, 1989, 4: 13-16.
3. Ализаде И.Т. Нарушение слуховой функции микроциркуляции у больных сахарным диабетом. Вестник оториноларингологии, 2007, 1: 11-13.
4. Беличева Э.Г. Стандарты диагностики острой и внезапной сенсоневральной тугоухости. Российская оториноларингология. Приложение, 2007: 609-613.
5. Yeo SW. Immune-mediated sensorineural hearing loss in a patient with ankylosing spondilitis: a case report. Otolaryngology-Head-surgery, 2001, 125, 1: 113-114.
6. Евдокимова А. Г., Ложкина М. В., Евдокимов В.В. и др. Клиническая эффективность иАПФ у пациентов с сердечно-сосудистыми заболеваниями. Сердце, 2012, II(6): 364-368.
7. Барышникова Г.А., Чорбинская С.А., Степанова И.И. Роль сартанов в лечении артериальной гипертонии: фокус на олмесартан. Consilium medicum, 2012, 10: 9-15.
8. Munzel T, Sinning C, Post F et al. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Annals of Medicine, 2008, 40: 180-196.
9. Pahkala K, Heinonen OJ, Lagstrom H et al. Vascular endothelial function and leisuretime physical activity in adolescents. Circulation, 2008, 118(23): 2353-2259.
10. Oparil S, Williams D, Chrysant SG et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. Journal of Clinical Hypertension, 2001, 3(5): 283-91.
11. Fliser D, Buchholz K, Haller H. For the European Trial on Olmesartan and Pravastatin in inflammation and Atheroscierosis (EUTOPIA) Investi. Circulation, 2004, 110: 1103-7.
12. Lorenzen JM, Neuhoeffer H, David S. Angiotensin II rezeptor blocker and statins lover elevated levels of osteopontin in essential hypertension -- results from the EUTOPIA Trial. Atherosclerosis, 2010, 209(1): 184-8.
13. Stumpe KO, Agabiti-Rosei E, Zielinski T et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmetsartan atherosclerosis Regression Evaluation (MORE) study. Ther. Adv. Cardiovasc. Dis., 2007, 1: 97-106.
14. Smith RD, Yokoyama H, Averill DB et al. The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics. Am J Cardiovasc Drugs, 2006, 6(5): 335-42.
15. Smith RD, Yokoyama ., Averill DB et al. Reversal of vascular hypertrophy in hypertensive patients through blocade of angiotensin II receptors. J Am Soc Hypertens., 2008, 2: 165-172.
16. Mediavilla JL, Fernandez-Torres C, JaOn Aguila F, Jimonez-Alonso J. Efecto de olmesartán medoxomilo sobre la rigidez arterial en pacientes con hipertensión arterial esencial. Medicina Clinica (Barcelona), 2007, 128: 726-729.
17. Kobori H, Ozawa Y, Suzaki Y, Nishiyama A. Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats. Journal of American Society of Nephrology, 2005, vol. 16 (7): 2073-2080.
18. Nangaku M, Miyata T, Sada T et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. Journal of American Society of Nephrology, 2003, 14 (5): 1212-1222.
19. Haller H, Viberti GC, Mimran A, Remuzzi G et al. Preventing microalbuminuria in patients with diabetes: rationale and design of the randomized olmesartan and diabetes microalbuminuria prevention (ROADMAP) study. Journal of Hypertension, 2006, 24: 403-408.
20. Haller H et al.; Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. The New English Journal of medicine, 2011, 364 (10): 907-917.
21. Патякина О.К. Актуальные вопросы клинической аудиологии. 1998.
22. Богданец С.А. Этиологические и патогенетические аспекты нейросенсорной тугоухости сосудистого генеза: автореф. дис. … канд. мед. наук. М., 2005: 15-16.
Review
For citations:
Evdokimova AG, Yunko SA, Gunchikov MV. Hypertension and sensorineural hearing loss: relevance of the problem and the specifics of treatment (focus on Olmesartan). Meditsinskiy sovet = Medical Council. 2015;(2):46-51. (In Russ.) https://doi.org/10.21518/2079-701X-2015-2-46-51
Views:
605
Email this article 